\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesThe DIREKTION project, funded under Horizon Europe Cluster 3 is accepting applications for the 2nd DIREKTION Awards, which aims to identify and reward promising near-to-deployment innovative solutions addressing key capability gaps in disaster resilience, and responding to the operational needs of emergency responders (firefighters, emergency services, civil protection, etc.).
This call specifically targets mature and demonstrable innovations with a Technology Readiness Level (TRL) between 5 and 7, with a strong focus on accelerating innovation uptake and supporting the transition of validated solutions towards wider operational adoption across Europe.
The call is open to solution providers established in EU Member States and Horizon Europe Associated Countries. Applications may be submitted by single entities or consortia.
A total of 10 solutions will be selected and awarded €10,000 each. Awarded solutions will benefit from:
Key information:
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The European Commission has published a new round of calls under the Digital Europe programme. The submission period for the following call topics will open on 21 April 2026: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
